Market Cap
$136.5M
ARMP
Armata Pharmaceuticals, Inc.
$3.52 ▲ +6.34%
Prev close $3.31Market cap$136.5M
ConsensusStrong Buy
12-mo target$17.50 (+397.2%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)12 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on ARMP right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
35 funds
Inst. Value
$15.8M
Inst. Activity
12 buys / 0 sells
SEC Reports
4
Price chart 30d -36.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 SEC
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for com
8-K — Impact 7/10
Sep 14, 2026 short_volume
Jul 20, 2026 SEC Short Volume: ARMP — 61.3% short (0.9M / 1.4M)
Short: 857,226 | Exempt: 19,274 | TRF Vol: 1,399,177 | Short Ratio: 61.3% | Off-exchange volume (dar
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, includ
8-K — Impact 5/10
Jul 10, 2026 Insider
Birx Deborah surrendered for taxes 14,041 shares
Chief Executive Officer @ $4.26 ($59.8K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
559,986 shares ($3.6M)
Jun 30, 2026 Inst.
May 13, 2026 SEC VANGUARD CAPITAL MANAGEMENT LLC — ADD
487,968 shares ($3.2M)
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 develop
8-K — Impact 6/10
Apr 24, 2026 Insider
Gilmer Daniel B. was granted 51,280 shares
Director
Analyst ratings buy % +2.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 8 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 2 covering analysts think ARMP trades over the next 12 months.
$17.50 +397.2% upside Strong Buy
Current$3.52 Low$15.00 Median$17.50 High$20.00 2 analysts
$15.00$20.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 1 neutral · avg impact 5.3/10.
BULLISH8-K7/10
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous p
Sep 14, 2026
BULLISH8-K5/10
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candi
Jul 20, 2026
BEARISH8-K6/10
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to
May 13, 2026
NEUTRAL8-K3/10
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with ex
Apr 27, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 14, 2026
short_volume
Short Volume: ARMP — 61.3% short (0.9M / 1.4M)
Short: 857,226 | Exempt: 19,274 | TRF Vol: 1,399,177 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
other
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biot
Sep 3, 2026
other
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biote
Aug 18, 2026
earnings_calendar
ARMP Q2 2026 Earnings Scheduled — 2026-08-18
Aug 12, 2026
earnings
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biote
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.56 | $-0.57–$-0.54 | 25.0% | +2.6% | 0↑ 2↓ | $0.0B | 2 |
| Next Q | $-0.40 | $-0.57–$-0.23 | 88.3% | +29.8% | 0↑ 1↓ | $0.0B | 2 |
| Current FY | $-1.86 | $-2.27–$-1.46 | 61.2% | +17.8% | 2↑ 0↓ | $0.0B | 2 |
| Next FY | $-1.45 | $-2.04–$-0.85 | 22.5% | -3.2% | 0↑ 2↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.555 | — |
| 7d ago | $-0.555 | — |
| 30d ago | $-0.570 | +0.015 |
| 60d ago | $-0.390 | -0.165 |
| 90d ago | $-0.390 | -0.165 |
Institutional ownership
Which big funds own ARMP (from quarterly 13F filings) and who is adding or trimming.
35 institutional holders with $15.8M total value (2,437,737 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, MILLENNIUM. Net buying activity: 12 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 559,986 | $3.6M | 23.0% | DOUBLED +760.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 487,968 | $3.2M | 20.0% | ADD +33.3% |
| MILLENNIUM MANAGEMENT LLC | 470,500 | $3.0M | 19.3% | ADD +82.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 270,550 | $1.8M | 11.1% | DOUBLED +136.2% |
| STATE STREET CORP | 129,600 | $839.8K | 5.3% | DOUBLED +155.1% |
| NORTHERN TRUST CORP | 89,791 | $581.8K | 3.7% | DOUBLED +264.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 81,354 | $527.2K | 3.3% | — |
| VANGUARD FIDUCIARY TRUST CO | 79,495 | $515.1K | 3.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 48,318 | $313.1K | 2.0% | ADD +25.5% |
| Bank of New York Mellon Corp | 29,749 | $192.8K | 1.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 65,050 | 559,986 | +760.9% | $3.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 366,028 | 487,968 | +33.3% | $3.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 257,992 | 470,500 | +82.4% | $3.0M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 114,555 | 270,550 | +136.2% | $1.8M |
| STATE STREET CORP | DOUBLED | 50,800 | 129,600 | +155.1% | $839.8K |
| NORTHERN TRUST CORP | DOUBLED | 24,646 | 89,791 | +264.3% | $581.8K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 38,496 | 48,318 | +25.5% | $313.1K |
| UBS Group AG | DOUBLED | 4,349 | 13,697 | +214.9% | $88.8K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1 | 10,819 | +1081800.0% | $70.1K |
| MORGAN STANLEY | ADD | 3,367 | 4,583 | +36.1% | $29.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 13 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Birx Deborah | Chief Executive Officer | TAX W/H | 14,041 | $4.26 | $59.8K |
| Apr 24, 2026 | Gilmer Daniel B. | Director | AWARD | 51,280 | — | — |
| Mar 14, 2026 | Birx Deborah | Chief Executive Officer | TAX W/H | 4,919 | $10.54 | $51.8K |
| Mar 14, 2026 | Kyme Pierre | Chief Business Officer | TAX W/H | 1,030 | $10.54 | $10.9K |
| Mar 9, 2026 | Peterson Todd C. | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Haimovitz Jules | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Schlesinger Sarah J. | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Birx Deborah | Chief Executive Officer | AWARD | 421,226 | — | — |
| Mar 9, 2026 | PATTI JOSEPH M | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | House David Duane | SVP, Finance, and PFO | AWARD | 109,885 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARMP.
Shares short
963,383
Settlement Sep 15, 2026
Change vs prior
+8.8%
Semi-monthly cycle
Days to cover
1.6
At avg daily volume
Of shares outstanding
≈2.6%
Estimate — not % of float
All ARMP filing & press-release reports (4)
- 8-K reportSep 14, 2026
- 8-K reportJul 20, 2026
- 8-K reportMay 13, 2026
- 8-K reportApr 27, 2026